Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation
NCT02502110Phase 4Unknown
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin in Atrial fibrillation (AFib) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Atrial Fibrillation recurrence rate at 90 days. Status: unknown.
02
Drugs
rosuvastatin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02502110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502110.